Investors

Investor Relations

Landing - Corporate Profile Text

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

More events are coming soon.

News Releases

July 22, 2024
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of
July 8, 2024
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of common stock